Blaze Bioscience and Fred Hutchinson Cancer Research Center Enter Into Collaboration and Option Agreement in Support of Optides Discovery Program

Wednesday, July 3, 2013 - 11:30 in Mathematics & Economics

Blaze Bioscience, Inc., a privately held biotechnology company developing Tumor PaintTM technology, and Fred Hutchinson Cancer Research Center, one of the nation's top cancer research and prevention centers and pioneer of bone marrow and stem cell transplantation, announced today a collaboration and option agreement to support the Hutchinson Center's Optides Discovery Program and advance drug candidates identified using the platform.

Read the whole article on Newswise - Scinews

More from Newswise - Scinews

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net